No Data
The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!
Industry pessimistic expectations may improve.
How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.
① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.
China Antibody-B (03681) and New Brightness-B (01952) have made progress in authorized cooperation, and the new BTK inhibitor SN1011 has achieved positive results in the phase 1b/2a clinical trial interim data.
This milestone result not only recognizes the huge potential of SN1011, but also marks an important milestone achievement in the authorized cooperation agreement between China Antibody and Yunding Xinyao.
China Antibody-B (03681.HK) granted 10.0624 million share options to director Wang Shanchun.
Granolith November 11th | China Antibody-B (03681.HK) announced that on November 11, 2024, the company has granted Wang Shanchun, an executive director, 10.0624 million share options under its share purchase plan, for subscription of a total of 10.0624 million new company shares.
China antibody-B (03681): Director Liu Wenyi resigns as non-executive director
China Antibody-B (03681) announced that Liu Wenyi has resigned as a non-executive director, effective September 2024...
SINOMAB BIO-B: Interim Report 2024
